Archive: December 2016

Novel Second-Line Treatments for Hepatocellular Carcinoma

Moderator Richard S. Finn, MD Discussants Catherine T. Frenette, MD, FAST, and Riccardo Lencioni, MD Abstract: There are 3 management approaches for patients with newly diagnosed hepatocellular carcinoma […]

Highlights in GEP-NETs From the 2016 NANETS Symposium

A SPECIAL MEETING REVIEW EDITION A Review of Selected Presentations From the 2016 North American Neuroendocrine Tumor Society Annual Symposium September 30-October 1, 2016 • Jackson, […]

Highlights in Ovarian Cancer From the 2016 ESMO Congress

A SPECIAL MEETING REVIEW EDITION A Review of Selected Presentations From the 2016 European Society for Medical Oncology Congress October 7-11, 2016 • Copenhagen, Denmark A […]

Highlights in Chronic Lymphocytic Leukemia From the 2016 American Society of Hematology Annual Meeting and Exposition

Special Reporting on:
• Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Twice Daily Dosing With the Highly Specific BTK Inhibitor, BGB-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated With Durable Responses in Patients (pts) With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
• Acalabrutinib Monotherapy in Patients With Ibrutinib Intolerance: Results From the Phase 1/2 ACE-CL-001 Clinical Study
• Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
• Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination With Bendamustine and Rituximab in Patients With Relapsed/Refractory CLL
• CLL2-BIG – A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial
PLUS Meeting Abstract Summaries
With Expert Commentary by:
Susan M. O’Brien, MD
Associate Director for Clinical Sciences, Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Clinical Trials & Research
Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
University of California, Irvine, Orange, California

Back to Archive